FIRST STEERING COMMITTEE OF 2025
March, 2025
We had the pleasure of gathering for our quarterly steering committee, an excellent opportunity to share and discuss the latest advancements across all project work packages.
A big thank you to everyone for the insightful presentations and for driving the project forward with such dedication. Looking forward to the next milestones!
COMITY DIGESTIF AT GUSTAVE ROUSSY
March, 2025
We extend our heartfelt thanks to the Comité Digestif at Gustave Roussy, especially Professor Michel Ducreux, Head of the Digestive Oncology Department, and Dr. Alice Boilève, Chief Resident in Medical Oncology, for their invaluable support of our project. Their clinical expertise and commitment have been essential in driving forward the RHU initiative, particularly the ORGANOTREAT clinical trial. This collaboration marks a significant milestone in accelerating innovation in digestive oncology, and we are truly grateful for their partnership.
CONGRATULATIONS TO OUR SCIENTIFIC COORDINATOR, FANNY JAULIN!
February, 2025
We are thrilled to announce that Fanny Jaulin, has been honored with the Prix du Palmarès des Inventeurs en Santé by Le Point magazine! 🎉
This prestigious award recognizes her outstanding contributions to health research and innovation. We couldn’t be prouder of her remarkable achievements and dedication to advancing science.
ORGANOIDS FOR FUNCTIONAL PRECISION MEDICINE IN ADVANCED PANCREATIC CANCER
October, 2024
Our study in Gastroenterology demonstrates that patient-derived organoids (PDOs) can be effectively implemented in clinical practice for patients with advanced refractory pancreatic ductal adenocarcinoma (PDAC). The research reports a 62% success rate in generating PDOs, with 91% of cases identifying at least one effective treatment option through ex vivo drug testing. These findings suggest that PDO-based functional precision medicine could offer significant therapeutic benefits for PDAC patients.
META AI AND ORAKL ONCOLOGY COLLABORATE TO ADVANCE PRECISION ONCOLOGY
February, 2025
Meta AI has teamed up with Orakl Oncology to apply its powerful DinoV2 foundation model to real patient-derived tumor models. This collaboration aims to accelerate the discovery of targeted cancer treatments by combining cutting-edge AI with biologically relevant data; an approach that aligns closely with RHU ORGANOMIC’s mission to bring personalized, data-driven innovation to oncology.
INVERTED APICOBASAL POLARITY IN HEALTH AND DISEASE
March, 2024
Our recent review in the Journal of Cell Science explores the phenomenon of inverted apicobasal polarity, highlighting its implications for tissue development and disease progression, including cancer.
ROLE OF MOLECULAR BIOLOGY IN THE MANAGEMENT OF PANCREATIC CANCER
July, 2024
Our recent review in the World Journal of Gastrointestinal Oncology examines the role of molecular biology in managing pancreatic cancer, highlighting how molecular insights can inform diagnosis, treatment strategies, and patient outcomes.
KRAS, A NEW TARGET FOR PRECISION MEDICINE IN COLORECTAL CANCER?
October, 2024
Our recent review in Cancers discusses the potential of targeting KRAS mutations for precision medicine in colorectal cancer, examining current challenges and future therapeutic strategies.
First RHU Steering Committee meeting of 2024
March 6, 2024
Our first RHU Steering Committee meeting of 2024 was an excellent opportunity for the PhD students within our consortium to showcase their remarkable progress.
Kudos to them for their dedication and hard work! Raphael MERAND, Valentin BONNET, Emmanouil Angelidakis.
New Publication in PNAS!
March 2024
Valentin Bonnet, PhD student in Charles Baroud’s lab at Institut Pasteur published an article in PNAS on the impact of the APC gene mutation on T-cell engagement and killing of cancer spheroids.
PRECISION MEDICINE FOR KRAS WILD-TYPE PANCREATIC ADENOCARCINOMAS
January, 2024
Our study in the European Journal of Cancer highlights that patients with KRAS wild-type pancreatic adenocarcinomas exhibit distinct characteristics, including longer overall survival and a higher prevalence of actionable molecular alterations, suggesting that precision medicine could be particularly beneficial for this subgroup.
CODON-SPECIFIC KRAS MUTATIONS PREDICT SURVIVAL IN ADVANCED PANCREATIC CANCER
March 2024
Our study in ESMO Gastrointestinal Oncology indicates that patients with pancreatic ductal adenocarcinoma (PDAC) harboring KRAS G12 mutations experience worse overall survival compared to those with other KRAS mutations, underscoring the prognostic significance of specific KRAS codon alterations in PDAC.
FIRST RHU-ORGANOMIC ANNUAL MEETING
December 12, 2023
We are thrilled to announce the successful culmination of our first annual meeting, held on December 12th, 2023! 🌟✨
A heartfelt congratulations to our incredible team for their hard work, dedication, and relentless pursuit of our project’s goals. Your passion and commitment are the driving forces behind our success, and we couldn’t be prouder of what we’ve achieved together.
A big THANK YOU to everyone who attended the meeting and especially to the ANR for their valuable input!
Here’s to a year of collaboration, innovation, and continued success! Cheers to an amazing team and an even brighter future ahead!
26th MICCAI CONFERENCE
October 8-12, 2023
Léo Fillioux (MICS, CentraleSupélec) presented his paper on the use of structured state space models as an emerging alternative for sequence modelling in digital pathology, entitled “Structured State Space Models for Multiple Instance Learning in Digital Pathology”, for the 26th international conference on Medical Image Computing and Computer Assisted Intervention (MICCAI) taking place in Vancouver, Canada, on October 8-12, 2023.
ESMO CONGRESS 2023
June 28 – July 1, 2023
Alice Boilève (Gustave Roussy), won Best Poster at the ESMO congress on Gastrointestinal Cancer taking place in Barcelona.
The poster, entitled “Organoids as tools for functional precision oncology in advanced pancreaticcancer”, describes a prospective monocentric study that aims to implement PDO-based functional precision oncology for PDAC.
CONSORTIUM AGREEMENT
Signed on April 7th, 2023
The consortium agreement set the framework for a successful project implementation (i.e. settled all issues that might hamper the smooth and seamless cooperation of the different actors for the different parts of the project).
FIRST ANNUAL REPORT FOR THE ANR
April 13th, 2023
The annual report is a comprehensive document that provides an overview of ORGANOMIC’s progress, achievements, challenges, and financial status over the course of a year, offering valuable insights into the project’s performance and outcomes to the ANR, the funding institution.
ANR FINANCIAL AID CONTRACT
Signed on April 19th, 2023
This formal agreement outlines the terms and conditions under which the grant is provided to the consortium, specifying repayment terms, obligations, and any associated conditions.
